Hexon-modified adenovirus vectors

六邻体修饰的腺病毒载体

• 批准号: 7244039
• 负责人: Dmitry Shayakhmetov
• 金额: $ 22.72万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-06-01 至 2009-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7244039
• 关键词: Adenovirus Vector; Adenovirus hexon capsid protein; Adenoviruses; Amino Acid Sequence; Amino Acids; Anthrax disease; Appendix; Binding; Biological Assay; Biology; Blood; Blood Circulation; Capsid; Capsid Proteins; Cell Communication; Cell surface; Cells; Charge; Clinical Trials; Coagulation Process; Complement; Complex; Data; Deposition; Development; Disruption; Distant; Dose; Drug Kinetics; Electrostatics; Fiber; Galactosidase; Gene Transfer; Genes; Goals; Green Fluorescent Proteins; Heparan Sulfate Proteoglycan; Hepatocyte; Human; In Vitro; Infection; Inflammatory; Interleukin-12; Interleukin-6; Kinetics; Knowledge; Kupffer Cells; Lead; Life; Liver; Liver Circulation; Localized; Mediating; Messenger RNA; Metastatic Neoplasm to the Liver; Minor; Modification; Molecular; Mus; Mutate; Mutation; Organ; Peptide Sequence Determination; Plasma; Positioning Attribute; Process; Property; Proteins; Range; Reporter Genes; Research Personnel; Risk; Role; Route; Serotyping; Structural Protein; Surface; Testing; Therapeutic Intervention; Time; Tissues; Toxic effect; Transgenic Organisms; Vaccination; Viral Vector; Virion; Virus; base; cell type; cellular transduction; chemokine; cytokine; human disease; improved; in vivo; interest; lung Carcinoma; mouse model; neoplastic cell; particle; penton base; prevent; receptor; uptake; vector; virus host interaction

DESCRIPTION (provided by applicant): Adenovirus vectors (Ad) are the second largest group of viral vectors extensively used in clinical trials in the US. The interest in Ad has recently expanded due to its potential as a vector for vaccination against anthrax and other life threatening infection agents. Despite significant knowledge regarding Ad interactions with cells in vitro, the molecular mechanisms governing infectivity, bio-distribution and toxicity of systemically applied Ad remain poorly understood. Numerous studies of Ad pharmacokinetics in vivo have shown that within the first few minutes after systemic application, more than 90% of the virus is cleared from the circulation by the liver, and that the liver is the predominant organ in the body transduced with Ad after systemic application. Our recent data suggest, however, that liver-mediated virus clearance occurs via two distinct molecular mechanisms. The first mechanism involves fiber-dependent receptor-mediated interactions of Ad with liver cells. The second mechanism, responsible for clearance of the bulk of systemically applied virus, does not depend on fiber-hepatic cell interactions. We hypothesized that hexon, the major Ad structural protein, is the main determinant mediating virus trapping in liver tissue independently of fiber-cellular receptor interactions. The overall goal of this study is to further our understanding of molecular mechanisms underlying liver-mediated Ad clearance from the blood, and to construct a safe capsid-modified vector, efficiently transducing target cells after systemic application at lower administered doses. The specific aims of the current proposal are: 1. To evaluate the role of Ad hexon in virus clearance from the blood using wild type Ads of different serotypes; 2. To develop Ad5-based vectors with mutated hexons and analyze their bio-distribution and persistence in circulation in a mouse model; and 3. To analyze efficacy of tumor cell targeting and systemic toxicity of hexon-mutated Ad5-based vectors upon their intravascular administration in a mouse model. These studies will dramatically improve our understanding of the mechanisms governing Ad-host interactions in vivo and may ultimately lead to the development of safe and efficient Ad vectors for the therapy of a wide range of inborn and acquired human diseases.

描述（由申请人提供）：腺病毒载体（Ad）是美国临床试验中广泛使用的第二大病毒载体。对Ad的兴趣最近扩大了，因为它有可能作为针对炭疽和其他威胁生命的感染因子接种疫苗的媒介。尽管对体外Ad与细胞的相互作用有重要的了解，但控制系统应用Ad的感染性、生物分布和毒性的分子机制仍然知之甚少。大量的体内Ad药代动力学研究表明，在全身应用后的最初几分钟内，90%以上的病毒被肝脏从循环中清除，并且肝脏是全身应用后Ad转导的主要器官。然而，我们最近的数据表明，肝脏介导的病毒清除通过两种不同的分子机制发生。第一种机制涉及纤维依赖性受体介导的Ad与肝细胞的相互作用。第二种机制，负责清除大部分系统应用的病毒，不依赖于纤维-肝细胞相互作用。我们假设六邻体，主要的Ad结构蛋白，是独立于纤维细胞受体相互作用介导病毒在肝组织中捕获的主要决定因素。本研究的总体目标是进一步了解肝介导的Ad从血液中清除的分子机制，并构建一种安全的衣壳修饰载体，在系统应用低剂量后有效地转导靶细胞。当前提案的具体目标是：1。利用不同血清型的野生型Ad，评价Ad六邻体在血液病毒清除中的作用；2. 构建ad5突变六联体载体，分析其在小鼠模型中的生物分布和循环持久性；和3。目的：分析六己体突变ad5载体在小鼠血管内给药后对肿瘤细胞的靶向作用和全身毒性。这些研究将极大地提高我们对体内Ad-宿主相互作用机制的理解，并可能最终导致开发安全有效的Ad载体，用于治疗广泛的先天性和获得性人类疾病。